Lactose (India)

Lactose (India) EBITDA per Share

The EBITDA per Share of Lactose (India) (524202.BO) as of Nov 13, 2026 is 10.12 INR. In the previous year, EBITDA per Share was 14.63 INR — a change of -30.83% (lower).

EBITDA per Share

10.12INR

YoY

-30.83%

Last updated:

EBITDA per Share of Lactose (India) is 2026 10.12 INR. EBITDA per Share of Lactose (India) was 2025 14.63 INR. It decreases by -30.83% lower compared to the previous year.

The Lactose (India) EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
7.63 INR
Jan 1, 2020
7.36 INR
Jan 1, 2021
4.94 INR
Jan 1, 2022
9.74 INR
Jan 1, 2023
9.10 INR
Jan 1, 2024
15.99 INR
Jan 1, 2025
14.63 INR
Jan 1, 2026
10.12 INR
The Lactose (India) EBITDA per Share history
YEAREBITDA per ShareYoY
10.12INR-30.83%
14.63INR-8.56%
15.99INR+75.77%
9.10INR-6.56%
9.74INR+97.04%
4.94INR-32.86%
7.36INR-3.49%
7.63INR+71.63%
4.44INR-62.13%
11.74INR+9.19%
10.75INR+164.12%
4.07INR+331.62%
0.94INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lactose (India) Stock analysis

What does Lactose (India) do? Lactose India Ltd. generates revenue through the manufacturing of pharmaceutical products, primarily lactose monohydrate and disaccharide lactulose. The company produces dry granulated, film and lacquer coated tablets, and offers prebiotic-galacto-oligosaccharides (GOS) for applications in dairy, beverages, bakery, infant nutrition, clinical nutrition, children's products, and geriatric nutrition. Its plant in Vadodara, Gujarat, has an installed capacity of 180 metric tons annually for pharma color coatings. The firm serves segments including liquid dosage forms, solid dosage forms, excipients, and active pharmaceutical ingredients. The company's main products are lactose monohydrate, lactulose, and GOS, which are sold to pharmaceutical manufacturers and food industry players. Lactose monohydrate is used as an excipient in solid dosage forms, while lactulose serves as an active pharmaceutical ingredient. GOS is marketed for use in infant nutrition, clinical nutrition, and other food applications. The plant in Vadodara supports production of these products alongside pharma color coatings. Lactose India Ltd. targets pharmaceutical companies requiring excipients and active ingredients, as well as food and beverage manufacturers seeking prebiotic additives. The firm's product range includes lactose monohydrate for solid dosage forms, lactulose for active pharmaceutical ingredients, and GOS for nutritional applications across multiple consumer segments. Its production capabilities support the growing demand for pharmaceutical and functional food ingredients in India. Lactose (India) is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lactose (India) stock

EBITDA per Share of Lactose (India) is 10.12 INR in 2026.

EBITDA per Share of Lactose (India) changed from 14.63 INR to 10.12 INR, representing a -30.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Lactose (India) since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Lactose (India)

All Key Metrics — Lactose (India)